Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
 32nd Annual Meeting - EconoTimes)
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, previously announced that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, has been selected for a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland.
Five Prime will host a conference call and live audio webcast on Saturday, November 11, 2017, at 5:45 p.m. (ET). Lewis T. “Rusty” Williams, President and Chief Executive Officer, Aron Knickerbocker, Chief Operating Officer, Helen Collins, Chief Medical Officer and Dr. Zev Wainberg, Assistant Professor of Medicine at UCLA, will review the data presented at SITC earlier that day.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 4092848.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT:
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
[email protected]
